Epidemiology of Non-Alcoholic Fatty Liver Disease
The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide. The prevalence of NAFLD in the general population of Western countries is 20–30%. About 2–3% of the general population is estimated to have non-alcoholic steatohepatitis (NASH), which may progress to liver cirrhosis and hepatocarcinoma. As a rule, the prevalence of NAFLD is higher in males and increases with increasing age, and it is influenced by the diagnostic method and the characteristics of the population, especially lifestyle habits. Population-based studies provide better estimates of the prevalence of NAFLD as compared to autoptic and clinical studies, but few such studies have been performed to date. The diagnosis of NAFLD in population studies is usually obtained by ultrasonography, which is known to underestimate the prevalence of fatty liver. The Dallas Heart Study and the Dionysos Study reported that 30% of the adults in the USA and 25% in Italy have NAFLD. In these studies, 79% and 55% of patients with NAFLD had normal aminotransferase levels, showing that liver enzymes are not surrogate markers of NAFLD in the general population. Noninvasive markers such as the fatty liver index obtained from the Dionysos Study may be useful to screen for NAFLD in the general population. The most important risk factors for NAFLD are male gender, age, obesity, insulin resistance and the cardiometabolic alterations that define the metabolic syndrome. The prevalence of NAFLD is 80–90% in obese adults, 30–50% in patients with diabetes and up to 90% in patients with hyperlipidemia. The prevalence of NAFLD among children is 3–10%, rising up to 40–70% among obese children. Moreover, pediatric NAFLD increased from about 3% a decade ago to 5% today, with a male-to-female ratio of 2:1. The incidence and natural history of NAFLD are still not well defined, but it is recognized that the majority of individuals with NAFLD do not develop NASH. The incidence of NAFLD is probably increasing in Western countries, strictly linked to lifestyle habits.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prevalence of NAFLD among normal-weight children is 3–10%, rising up to 40–70% among obese children”
From Lack of Exercise Is a Major Cause of Chronic Diseases (2012) · cites this paper as [33]
Citations
Cites
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352 · cited 1×
“In the literature, many competing definitions of the MS are available. The definition recently put forth by the International Federation for the Study of Diabetes (IDF) [”
BackgroundNonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664 · cited 1×
“It is important to note that this prevalence is partly dependent upon the method used to diagnose FL, the method used to assess alcohol intake and the cutoff point used to exclude ‘relevant’ alcohol intake, see table 2 , with respective references [ , , , , , , , , , , , , , , , , , , , , , ,”
MethodNonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · cited 1×
“] and 15p in Asian countries [ , , , , , , , , , ,”
Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,042 · cited 1×
“We suggest to expand the number of prospective cohort studies in the general population, even if they are more expensive and difficult to handle, because they give more reliable results about the burden of disease attributable to NAFLD. The most simple, noninvasive and practical method for diagnosing FL in population…”
BackgroundSelf-citationLudwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679 · cited 1×
“Population and clinical studies have increasingly shown that most cases of NAFLD are associated with the metabolic syndrome (MS), so that NAFLD is presently considered the hepatic manifestation of MS [”
BackgroundNonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154 · cited 1×
“Definition and Classification of Non-Alcoholic Fatty Liver DiseaseNon-alcoholic fatty liver disease (NAFLD) is operationally defined as fatty liver (FL), i.e. an accumulation of lipids inside the hepatocytes exceeding 5p of the weight of the liver, without hepatitis B virus or hepatitis C virus infection and in the ab…”
BackgroundIndependent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
Angulo, P., Keach, J. C., Batts, K. P., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510300604 · Cited by 1,610 · cited 1×
“A recent study showed that 27p of US adults have raised levels of liver enzymes and that 79p of these values cannot be explained by the most common causes of liver disease [ , , , , , , , ,”
BackgroundAssociation of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,568 · cited 1×
“While steatosis is usually associated with a benign prognosis, steatohepatitis and fibrosis may progress to cirrhosis and possibly hepatocarcinoma.During the last decade, the number of studies on NAFLD has grown exponentially, and new concepts have been acquired by the scientific community. We now know that NAFLD is o…”
Background
Research works printed but not linked: 7
- 10.1097%2f00005176-200001000-00017 · doi:10.1097/00005176-200001000-00017 · Paper page
- 10.1016%2fs1590-8658%2802%2980194-3 · DOI
- 10.1111%2fj.1572-0241.2001.04052.x · doi:10.1111/j.1572-0241.2001.04052.x · Paper page
- 10.1016%2fs0168-8278%2801%2900094-0 · DOI · Paper page
- 10.1111%2fj.1572-0241.1999.01451.x · doi:10.1111/j.1572-0241.1999.01451.x · Paper page
- 10.3109%2f00365527709181339 · DOI · Paper page
- 10.1053%2fgast.2001.25540 · DOI · Paper page
Cited by
Items 301–400 of 1,000
Ji, W., Xue, M., Zhang, Y., Yao, H., & Wang, Y. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.846118 · Cited by 50
“NAFLD is closely related to overweight or obesity, hyperlipidemia, type 2 diabetes mellitus (T2DM) and other chronic metabolic diseases: the prevalence of NAFLD is 60–90%, 27–92%, and 28–70% in obesity, hyperlipidemia and T2DM, respectively (4).”
BackgroundEffects of rosuvastatin and/or β-carotene on non-alcoholic fatty liver in rats.
el-Din, S. H. S., El-Lakkany, N. M., El-Naggar, A. A., Hammam, O. A., El‐Latif, H. A. A., Ain-Shoka, A. A., & Ebeid, F. (2015) · PubMed Central · Cited by 44
Ming, J., Xu, S., Gao, B., Liu, G., Ji, Y., Yang, F., Jia, Y., Fang, Y., & Ji, Q. (2015) · Liver International · doi:10.1111/liv.12851 · Cited by 44
Arase, Y., Suzuki, F., Ikeda, K., Kumada, H., Tsuji, H., & Kobayashi, T. (2009) · Journal of Gastroenterology · doi:10.1007/s00535-009-0091-1 · Cited by 44
Abdelaziz, R., Elbasel, M., Esmat, S., Essam, K., & Abdelaaty, S. (2015) · Digestion · doi:10.1159/000439083 · Cited by 44
Wu, Z., Martinez, M. E., Germain, D. L. S., & Hernández, A. (2016) · Endocrinology · doi:10.1210/en.2016-1680 · Cited by 45
Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway
Lu, Z., He, B., Chen, Z., Yan, M., & Wu, L. (2020) · BMC Immunology · doi:10.1186/s12865-020-00358-9 · Cited by 43
Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease
Federico, A., Zulli, C., de Sio, I., Prete, A. D., Dallio, M., Masarone, M., & Loguercio, C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i45.16841 · Cited by 50
Mouse models of metabolic liver injury
Ramadori, P., Weiskirchen, R., Trebicka, J., & Streetz, K. L. (2015) · Laboratory Animals · doi:10.1177/0023677215570078 · Cited by 43
“Notably, the most important risk factors for NAFLD in humans are male gender, age, obesity, insulin resistance and cardio-metabolic alterations that define the metabolic syndrome.(1) Moreover, several genetic mouse models have been shown to provide a base for the development of fatty liver diseases and NASH developmen…”
BackgroundBuscarini, E., Conte, D., Cannizzaro, R., Bazzoli, F., Boni, M. D., Fave, G. D., Farinati, F., Ravelli, P., Testoni, P. A., Lisiero, M., et al. (2014) · Digestive and Liver Disease · doi:10.1016/j.dld.2014.02.019 · Cited by 45
Self-citationAbangah, G., Yousefi, A., Asadollahi, R., Veisani, Y., Rahimifar, P., & Alizadeh, S. (2014) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.12669 · Cited by 43
“In addition, among obese people is far higher than general population (11, 12).”
BackgroundDepner, C. M., Torres‐Gonzalez, M., Tripathy, S., Milne, G. L., & Jump, D. Β. (2012) · Journal of Nutrition · doi:10.3945/jn.112.158865 · Cited by 45
Soleimani, D., Paknahad, Z., Askari, G., Iraj, B., & Feizi, A. (2016) · Advanced Biomedical Research · doi:10.4103/2277-9175.174962 · Cited by 43
“[6] The prevalence of NAFLD in obese, diabetic, and dyslipidemic patients has been estimated to be about 80–90%, 30–50%, and 90%, respectively.[7]”
BackgroundEnhanced Steatosis and Fibrosis in Liver of Adult Offspring Exposed to Maternal High-Fat Diet
Thompson, M. D., Cismowski, M. J., Trask, A. J., Lallier, S. W., Graf, A. E., Rogers, L. K., Lucchesi, P. A., & Brigstock, D. R. (2016) · Gene Expression · doi:10.3727/105221616x692135 · Cited by 42
Li, D., Zheng, J., Hu, Y., Hou, H., Hao, S., Liu, N., & Wang, Y. (2017) · Pharmacognosy Magazine · doi:10.4103/pm.pm_584_16 · Cited by 43
Zhao, C., Wu, X., Yi, H., Chen, R., & Fan, G. (2021) · Chemistry & Biodiversity · doi:10.1002/cbdv.202100033 · Cited by 44
“NAFLD in adults ranges from 10% to 30%, of which 10% to 20% are non-alcoholic steatohepatitis (NASH).([65])”
BackgroundFerraioli, G., Tinelli, C., Lissandrin, R., Zicchetti, M., Rondanelli, M., Perani, G., Bernuzzi, S., Salvaneschi, L., & Fìlice, C. (2014) · Hepatology International · doi:10.1007/s12072-014-9573-1 · Cited by 46
Kirovski, G., Dorn, C., Huber, H., Moleda, L., Niessen, C., Wobser, H., Schacherer, D., Buechler, C., Wiest, R., & Hellerbrand, C. (2011) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2011.08.001 · Cited by 43
Branched chain amino acids and metabolic regulation
Wang, C., & Guo, F. (2013) · Chinese Science Bulletin · doi:10.1007/s11434-013-5681-x · Cited by 47
Non-alcoholic fatty liver disease: need for a balanced nutritional source
Veena, J., Anjaneyulu, M., Sidgiddi, S., & Subramaniam, S. (2014) · British Journal Of Nutrition · doi:10.1017/s0007114514002591 · Cited by 46
“The prevalence of NAFLD has been found to be higher in males and increases with the progression of age((9)).”
BackgroundProbiotics in non-alcoholic fatty liver disease: which and when
Abenavoli, L., Scarpellini, E., Rouabhia, S., Balsano, C., & Luzza, F. (2013) · Annals of Hepatology · doi:10.1016/s1665-2681(19)30997-4 · Cited by 45
Luo, X., Yang, Y., Shen, T., Tang, X., Xiao, Y., Zou, T., Xia, M., & Ling, W. (2012) · Nutrition & Metabolism · doi:10.1186/1743-7075-9-34 · Cited by 44
Bae, J., Kumazoe, M., Fujimura, Y., & Tachibana, H. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.10.014 · Cited by 43
Giagulli, V. A., Castellana, M., Murro, I., Pelusi, C., Guastamacchia, E., Triggiani, V., & Pergola, G. D. (2019) · Nutrients · doi:10.3390/nu11122975 · Cited by 45
“A prospective study, performed for over five years in 181 men with obesity, including 72 patients affected by T2DM, treated by parenteral testosterone undecanoate 1000 mg/12 weeks, showed a significant and sustained reduction in body weight, BMI and waist circumference.”
BackgroundInfluentialPrasomthong, J., Limpeanchob, N., Daodee, S., Chonpathompikunlert, P., & Tunsophon, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-11027-9 · Cited by 45
“The rats were randomly divided into 5 groups: (1) control group (C; n = 7) were fed a normal diet, (2) high-fat diet group (HFD; n = 7) were fed a high-fat diet, (3) high-fat diet treated with simvastatin group (HFD + SIM; n = 7) were fed a high fat diet with 40 mg/kg/day of simvastatin by oral gavage, (4) high-fat di…”
MethodSteatosis and Steatohepatitis: Complex Disorders
Bettermann, K., Hohensee, T., & Haybaeck, J. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15069924 · Cited by 48
Liu, W. Y., Lu, D. J., Du, X. M., Sun, J. Q., Ge, J., Wang, R. W., Wang, R., Zou, J., Xu, C., Ren, J., et al. (2014) · BMC Public Health · doi:10.1186/1471-2458-14-48 · Cited by 40
Huang, W., Wang, G., Xia, Y., Xiong, Z., & Ai, L. (2020) · Food & Nutrition Research · doi:10.29219/fnr.v64.3751 · Cited by 44
“Internationally, effective and complete probiotic strains must conform to the following four criteria: (1) beneficial to the host, (2) normal colonisation at a specific location in the host, (3) growth and survival at a specific location in/on the host and (4) maintenance of viability and activity during production an…”
BackgroundFukuda, T., Hamaguchi, M., Kojima, T., Mitsuhashi, K., Hashimoto, Y., Ohbora, A., Kato, T., Nakamura, N., & Fukui, M. (2016) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000736 · Cited by 45
Vecchi, V. L., Soresi, M., Giannitrapani, L., Carlo, P. D., Mazzola, G. C., Colletti, P., Terranova, A., Vizzini, G. B., & Montalto, G. (2012) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2012.01.011 · Cited by 41
“Before the era of highly-active antiretroviral therapy (HAART), HS prevalence in HIV-infected patients was about 30%,(2) similar to the general population.(3) HIV-infected patients may be at particular risk of HS, as HIV infection per se can result in fat deposition in the liver.”
BackgroundYe, J.-H., Chao, J., Chang, M., Peng, W., Cheng, H., Liao, J., & Pao, L. (2016) · Scientific Reports · doi:10.1038/srep33102 · Cited by 46
Cueto-Galán, R., Barón-López, F. J., Valdivielso, P., Pintó, X., Corbella, E., Gómez‐Gracia, E., & Wärnberǵ, J. (2017) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2017.04.030 · Cited by 43
Xu, J., Li, L., Wang, Y. Q., Li, Y., Shan, M., Sun, S., Yu, Y. W., & Wang, B. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m077016 · Cited by 42
“This article is available online at http://www.jlr.org Journal of Lipid Research Volume 59, 2018 35 Copyright © 2018 by the American Society for Biochemistry and Molecular Biology, Inc. Nonalcoholic fatty liver disease (NAFLD), one of the most common chronic liver disorders, affects up to onethird of adults in the USA…”
BackgroundFriedrich, D., Marschall, H., & Lammert, F. (2018) · BMC Gastroenterology · doi:10.1186/s12876-018-0805-z · Cited by 40
de Oliveira, D. G., Ghetti, F. D. F., Moreira, A. P. B., Hermsdorff, H. H. M., de Oliveira, J. M., & Ferreira, L. E. V. V. D. C. (2018) · European Journal of Nutrition · doi:10.1007/s00394-018-1776-0 · Cited by 40
Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis
Ratziu, V., Ghabril, M., Romero-Gomez, M., & Svegliati-Baroni, G. (2019) · Transplantation · doi:10.1097/tp.0000000000002483 · Cited by 38
Sáez-López, C., Salcedo-Allende, M. T., Hernandez, C., Simó-Servat, O., Simó, R., & Selva, D. M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00740 · Cited by 38
Rahmanabadi, A., Mahboob, S., Amirkhizi, F., Hosseinpour-Arjmand, S., & Ebrahimi‐Mameghani, M. (2019) · Food & Function · doi:10.1039/c9fo00449a · Cited by 43
Liu, Y., Liu, S., Huang, J., Zhu, Y., & Lin, S. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15799 · Cited by 41
Effects of Alcohol Consumption on Hepatocarcinogenesis in Japanese Patients With Fatty Liver Disease
Kawamura, Y., Arase, Y., Ikeda, K., Akuta, N., Kobayashi, M., Saitoh, S., Suzuki, F., Suzuki, Y., Inao, M., Mochida, S., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.11.019 · Cited by 43
Sellmann, C., Jin, C. J., Engstler, A. J., Bandt, J. P. D., & Bergheim, I. (2016) · European Journal of Nutrition · doi:10.1007/s00394-016-1287-9 · Cited by 40
Love, S., Mudasir, M. A., Bhardwaj, S. C., Singh, G., & Abdullah, S. T. (2017) · Oncotarget · doi:10.18632/oncotarget.15194 · Cited by 42
“The prevalence of NAFLD in the west is 20-30% and that of NASH is 2-3% [3].”
BackgroundAli, H., Shahzil, M., Moond, V., Shahzad, M., Thandavaram, A., Sehar, A., Waseem, H., Siddiqui, T. A., Dahiya, D. S., Patel, P., et al. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14010061 · Cited by 46
“The prevalence of MASLD in children is 3–10%, but it can increase to 40–70% among obese children [24].”
BackgroundPandey, A., Raj, P. S., Goru, S. K., Kadakol, A., Malek, V., Sharma, N., & Gaikwad, A. B. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.02.005 · Cited by 42
Enzymatic and nonenzymatic protein acetylations control glycolysis process in liver diseases
Li, J., Wang, T., Xia, J., Yao, W., & Huang, F. (2019) · The FASEB Journal · doi:10.1096/fj.201901175r · Cited by 39
“According to the statistics, ;20–30% and 2–3% of the population in the west suffer from NAFLD and NASH, respectively (5, 6), and.”
BackgroundSerum Ferritin Correlates With Liver Fat in Male Adolescents With Obesity
Mörwald, K., Aigner, E. S., Bergsten, P., Brunner, S. M., Forslund, A. H., Kullberg, J., Ahlström, H. K., Manell, H., Roomp, K., Schütz, S., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00340 · Cited by 40
Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases
Liu, J., Yang, D., Wang, X., Asare, P. T., Zhang, Q., Na, L., & Shao, L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.774335 · Cited by 45
Somi, M. H., Fatahi, E., Panahi, J., Havasian, M. R., & Judaki, A. (2014) · Bioinformation · doi:10.6026/97320630010575 · Cited by 39
Steinacher, D., Claudel, T., & Trauner, M. (2017) · Digestive Diseases · doi:10.1159/000454853 · Cited by 40
Mills, E. P., Brown, K. P. D., Smith, J. D., Vang, P. W., & Trotta, K. (2017) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018817741852 · Cited by 41
Gawrieh, S., Lake, J. E., Debroy, P., Sjoquist, J. A., Robison, M., Tann, M. A., Akisik, F. M., Bhamidipalli, S. S., Saha, C., Zachary, K. C., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000313 · Cited by 40
“study and 79% of patients with NAFLD in the Dallas Heart Cohort were noted to have normal ALT levels (<40 U/L in males and <31 U/L in women).[18,61] Limitations of this study include having a population of PWH predominantly on ART with viral suppression without a history of hepatitis B or C co-infection and who were w…”
Lycopene Improves Diet-Mediated Recuperation in Rat Model of Nonalcoholic Fatty Liver Disease
Piña–Zentella, R. M., Rosado, J. L., Gallegos‐Corona, M. A., Pérez, L. A. M., García, O. P., & Ramos‐Gómez, M. (2016) · Journal of Medicinal Food · doi:10.1089/jmf.2015.0123 · Cited by 38
“The nonalcoholic fatty liver disease (NAFLD) has become the most common liver disorder around the world.(1,2) Although NAFLD is not associated with short-term mortality, it could be aggravated from simple steatosis to nonalcoholic steatohepatitis (NASH), often resulting in cirrhosis and even hepatocellular cancer.”
Wang, H., Wang, D., Yang, L., Wang, Y., Jia, J., Na, D., Chen, H., Luo, Y., & Liu, C. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.11.012 · Cited by 40
Nones, R. B., Ivantes, C. A. P., & Pedroso, M. L. A. (2017) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000233 · Cited by 37
“While the former accounts for the majority of cases and has a benign course (2,7,8), the latter affects 10% of patients and is characterized by steatosis accompanied by signs of cell injury (hepatocellular ballooning) and liver inflammation.”
BackgroundResultTan, S., Georgousopoulou, E. N., Cardoso, B. R., Daly, R. M., & George, E. S. (2021) · BMC Geriatrics · doi:10.1186/s12877-021-02239-1 · Cited by 41
Integrated Liver and Plasma Proteomics in Obese Mice Reveals Complex Metabolic Regulation
Stocks, B., González-Franquesa, A., Borg, M. L., Björnholm, M., Niu, L., Zierath, J. R., & Deshmukh, A. S. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100207 · Cited by 40
“At the same time, NAFLD has a 25% prevalence in Western and Asian populations (7, 8), raising to 80% to 90% in obese individuals (7).”
BackgroundMolecular mechanisms of fatty liver in obesity
Gan, L., Xiang, W., Xie, B., & Yu, L. (2015) · Frontiers of Medicine · doi:10.1007/s11684-015-0410-2 · Cited by 44
“, the vast majority of NAFLD cases are seen in the obese population [1–7].”
BackgroundLi, Y., Xing, C., Tian, Z., & Ku, H.-C. (2012) · BMC Medical Genetics · doi:10.1186/1471-2350-13-113 · Cited by 42
Tokita, Y., Maejima, Y., Shimomura, K., Takenoshita, S., Ishiyama, N., Akuzawa, M., Shimomura, Y., & Nakajima, K. (2017) · Internal Medicine · doi:10.2169/internalmedicine.56.7115 · Cited by 37
“With the increasing prevalence of obesity, diabetes, and metabolic syndrome in the United States (US), non-alcoholic fatty liver disease (NAFLD) has become the most common disease of chronic liver damage in the US (1-3).”
BackgroundAssociation between nonalcoholic fatty liver disease and carotid atherosclerosis: a meta-analysis.
Cai, J. X., Zhang, S., & Huang, W. (2015) · Europe PMC (PubMed Central) · Cited by 37
Ajabnoor, G., Bahijri, S., Enani, S. M., Alsheikh, L., Ahmed, M. M., Alhozali, A. M., Alshali, K. Z., Eldakhakhny, B. M., Alamoudi, A. A., Al-Ahmadi, J., et al. (2023) · Diseases · doi:10.3390/diseases11010010 · Cited by 36
“The prevalence of NAFLD was reported to be higher in western countries, approximately 20–30%, compared with 15% in Asian countries [13].”
BackgroundResultThe Impact of Obesity and Metabolic Syndrome on Chronic Hepatitis B and Drug-Induced Liver Disease
Pais, R., Rusu, E. E., & Ratziu, V. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.09.015 · Cited by 38
Li, L., Zhang, L., Pan, S.-Y., Wu, X., & Yin, X. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2658-1 · Cited by 36
Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr−/− mice
Jump, D. Β., Depner, C. M., Tripathy, S., & Lytle, K. A. (2015) · Proceedings of The Nutrition Society · doi:10.1017/s002966511500244x · Cited by 41
“The prevalence of NAFLD has increased in parallel with incidence of central obesity((3,4)), and is now the most common fatty liver disease in developed countries((5)).”
Zhang, X., Gao, X., Zhang, P., Guo, Y., Lin, H., Diao, X., Liu, Y., Dong, C., Hu, Y., Chen, S., et al. (2017) · Medical Engineering & Physics · doi:10.1016/j.medengphy.2017.02.014 · Cited by 36
Shah, C., Mramba, L. K., Bishnoi, R., Bejjanki, H., Chhatrala, H. S., & Chandana, S. R. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.06.16 · Cited by 36
“The prevalence of NAFLD in the general population of western countries is 20–30%, with about 2–3% of the general population is estimated to have non-alcoholic steatohepatitis (NASH) which can progress to liver cirrhosis and HCC (14).”
BackgroundChen, L., Zhao, X., Liang, G., Sun, J., Lin, Z., Hu, R., Chen, P., Zhang, Z., Zhou, L., & Li, Y. (2017) · Nutrition & Metabolism · doi:10.1186/s12986-017-0208-0 · Cited by 37
Tian, J., Chen, X., Xia, C., Liu, H., Yan, H., Wang, G., & Wu, Z. (2019) · Scientific Reports · doi:10.1038/s41598-019-41371-2 · Cited by 36
Exploiting Common Aspects of Obesity and Alzheimer’s Disease
Tabassum, S., Misrani, A., & Yang, L. (2020) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2020.602360 · Cited by 36
Dichtel, L. E., Corey, K. E., Haines, M. S., Chicote, M. L., Kimball, A., Colling, C., Simon, T. G., Long, M. T., Husseini, J. S., Bredella, M. A., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac405 · Cited by 38
Elevation of liver enzymes within the normal limits and metabolic syndrome
Xia, M., Yan, H., Lin, H., Bian, H., Pan, B., Yao, X., Li, R.-K., Zeng, M., & Gao, X. (2011) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2011.05519.x · Cited by 37
Saad, D. Y., Soliman, M. M., Baiomy, A. A. A., Yassin, M. H., & El-Sawy, H. B. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-017-1833-x · Cited by 36
Sun, B. L., Sun, X., Kempf, C. L., Song, J. H., Casanova, N. G., Camp, S. M., Reyes Hernon, V., Fallon, M., Bime, C., Martin, D. R., et al. (2023) · The FASEB Journal · doi:10.1096/fj.202201972rr · Cited by 35
Glaser, T., Baiocchi, L., Zhou, T., Francis, H., Lenci, I., Grassi, G. B., Kennedy, L. L., Liangpunsakul, S., Glaser, S. S., Alpini, G. D., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15182 · Cited by 35
“(1) These diseases determine a condition of leaky gut as a consequence of the alteration of the normal bowel wall; (2) increased levels of PAMPS (LPS) are released in blood; (3) these in turn stimulate TLR4 pathway and liver inflammation.”
BackgroundNAFLD VS MAFLD. The evidence-based debate has come. Time to change?
García‐Compeán, D., & Jiménez-Rodríguez, A. R. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100765 · Cited by 38
Jiang, Z., Xu, C., Chang, X.-X., Li, W., Sun, L., Yang, X., & Yu, L.-F. (2013) · BMC Gastroenterology · doi:10.1186/1471-230x-13-110 · Cited by 35
Yang, Z., Wen, J., Qin, L., Tao, X., Ye, Z., He, M., Zhang, W., Huang, Y., Chen, L., Ling, C., et al. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.001 · Cited by 35
Alisi, A., Nobili, V., Ceccarelli, S., Panera, N., Stefanis, C. D., Vito, R. D., Vitali, R., Bedogni, G., Balsano, C., Cucchiara, S., et al. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.928205 · Cited by 37
“About 20–30% of the general population and 3–12% of the children worldwide are estimated to have NAFLD [1,2].”
BackgroundSelf-citationA pathogenetic link between non-alcoholic fatty liver disease and celiac disease
Abenavoli, L., Milić, N., LORENZO, A. D., & Luzza, F. (2012) · Endocrine · doi:10.1007/s12020-012-9731-y · Cited by 35
“The prevalence of NAFLD in Western countries, is about 30 % [2, 3].”
BackgroundTINIAKOS, D. G., Anstee, Q. M., & Burt, A. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6697-9.00005-4 · Cited by 37
Association between metabolic syndrome and liver histology among NAFLD patients without diabetes
Kanwar, P., Nelson, J. E., Yates, K. P., Kleiner, D. E., Ünalp–Arida, A., & Kowdley, K. V. (2016) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2016-000114 · Cited by 35
“To view please visit the journal (http://dx.doi.org/ 10.1136/bmjgast-2016000114) Received 25 July 2016 Revised 29 September 2016 Accepted 6 October 2016 1New York Methodist Hospital, Brooklyn, New York, USA 2Benaroya Research Institute, Seattle, Washington, USA 3Johns Hopkins University, Baltimore, Maryland, USA 4Nati…”
BackgroundInfluentialMarco‐Rius, I., von Morze, C., Sriram, R., Cao, P., Chang, G., Milshteyn, E., Bok, R., Ohliger, M. A., Pearce, D., Kurhanewicz, J. V., et al. (2016) · Magnetic Resonance in Medicine · doi:10.1002/mrm.26525 · Cited by 36
“This process is poorly controlled in diabetes, and it is now recognized that GNG is dysregulated in nonalcoholic fatty liver disease (NAFLD) (3), which has prevalence of 80–90% in obese adults (4).”
BackgroundCueto-Galán, R., Barón-López, F. J., Valdivielso, P., Pintó, X., Corbella, E., Gómez‐Gracia, E., & Wärnberǵ, J. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2016.11.032 · Cited by 41
Zhang, S., Zhu, P., Yuan, J., Cheng, K., Xu, Q., Chen, W., Pan, Z., & Zheng, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1149665 · Cited by 38
Ghasemi-rad, M., Mohammadi, A., & Habibpour (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s26011 · Cited by 34
Seth, R. K., Das, S., Kumar, A., Chanda, A., Kadiiska, M. B., Michelotti, G. A., Manautou, J. E., Diehl, A. M., & Chatterjee, S. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.10.029 · Cited by 36
Risk of Obesity-Related Cardiometabolic Complications in Special Populations: A Crisis in Asians
Abate, N. I., & Chandalia, M. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.046 · Cited by 41
Vahid, F., Shivappa, N., Hekmatdoost, A., Hébert, J. R., Poustchi, H., Shamsipour, A., Eslamparast, T., Meibodi, M., & Rahmani, D. (2018) · International Journal for Vitamin and Nutrition Research · doi:10.1024/0300-9831/a000571 · Cited by 34
Kwon, Y. D., Ko, K. O., Lim, J. W., Cheon, E. J., Song, Y. W., & Yoon, J. M. (2019) · Journal of Korean Medical Science · doi:10.3346/jkms.2019.34.e165 · Cited by 34
Serum ferritin levels do not predict the stage of underlying non-alcoholic fatty liver disease.
Chandok, N., Minuk, G. Y., Wengiel, M., & Uhanova, J. (2012) · PubMed · Cited by 34
Liver disease: an overlooked complication of diabetes mellitus
Arrese, M. A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.173 · Cited by 34
“Epidemiological figures show a high prevalence of NAFLD in Western countries”
Attia, D. I., Bantel, H., Lenzen, H., Manns, M. P., Gebel, M., & Potthoff, A. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13710 · Cited by 35
Milk thistle to treat non-alcoholic fatty liver disease: dream or reality?
Abenavoli, L., & Bellentani, S. (2013) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2013.842893 · Cited by 34
Self-citationTranslating Mechanism-Based Strategies to Break the Obesity−Cancer Link: A Narrative Review
Smith, L. A., O’Flanagan, C. H., Bowers, L. W., Allott, E. H., & Hursting, S. D. (2017) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2017.08.112 · Cited by 37
Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC
Liu, K., & McCaughan, G. W. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-8684-7_2 · Cited by 36
Luo, Q., Li, Y., Huang, C., Cheng, D., Ma, W., Xia, Y., Liu, W., & Chen, Z. (2019) · Molecules · doi:10.3390/molecules24162966 · Cited by 34
“The result from several studies suggested that obesity was an important risk factor for non-alcoholic fatty liver disease [4], hypertension [5], inflammation [6] and cancer [7].”
BackgroundKuroe, K., Furuta, M., Takeuchi, K., Takeshita, T., Suma, S., Shinagawa, T., Shimazaki, Y., & Yamashita, Y. (2021) · Journal Of Clinical Periodontology · doi:10.1111/jcpe.13415 · Cited by 41
Ali, A., Amin, M. J., Ahmed, M. U., Taj, A., Aasim, M., & Tabrez, E. S. (2021) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.38.1.4968 · Cited by 37
Karjoo, S., Auriemma, A., Fraker, T. R., & Bays, H. E. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100027 · Cited by 36
“NAFLD is the most common cause of chronic liver disease ( > 25% ofalladults)[2,3,11].”
BackgroundPapandreou, C., Bulló, M., Tinahones, F. J., Martínez‐González, M. Á., Corella, D., Fragkiadakis, G. A., López‐Miranda, J., Estruch, R., Fitó, M., & Salas‐Salvadó, J. (2017) · Nutrition & Metabolism · doi:10.1186/s12986-017-0213-3 · Cited by 35
Metadata
- Authors
- Bellentani, S., Scaglioni, F., Marino, M., & Bedogni, G.
- Venue
- Digestive Diseases
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 28
- Issue
- 1
- Pages
- 155-161
- ISSN
- 0257-2753 (ISSN-L)
- 1421-9875
- OpenAlex
- W2036047239
- Cited by
- 1,026
- References
- 77
- Citations by year
- 2026: 7 · 2025: 19 · 2024: 31 · 2023: 51 · 2022: 72 · 2021: 71 · 2020: 78 · 2019: 85 · 2018: 96 · 2017: 97 · 2016: 89 · 2015: 84 · 2014: 71 · 2013: 81 · 2012: 48
- FWCI
- 40.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Digestive Diseases (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, prevalence, nonalcoholic steatohepatitis, liver cirrhosis, hepatocellular carcinoma, risk factors, obesity, insulin resistance, metabolic syndrome, fatty liver index, NAFLD screening, pediatric NAFLD, incidence, lifestyle, transaminases
- MeSH terms
- Adult, Aged, Fatty Liver, Female, Humans, Italy, Male, Middle Aged, Risk Factors, United States, Prevalence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.